Improvement in quality of life and cardiac function after catheter ablation for asymptomatic persistent atrial fibrillation.
B‐type natriuretic peptide
atrial fibrillation
catheter ablation
quality of life
reverse remodeling
Journal
Journal of arrhythmia
ISSN: 1880-4276
Titre abrégé: J Arrhythm
Pays: Japan
ID NLM: 101263026
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
08
08
2020
revised:
17
10
2020
accepted:
29
10
2020
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
Catheter ablation (CA) for atrial fibrillation (AF) is widely performed. However, the indication for CA in patients with asymptomatic persistent AF is still controversial. Among 259 consecutive patients who were hospitalized for initial CA of AF, a total of 45 patients who had asymptomatic persistent AF were retrospectively analyzed. Quality of life (QOL) before and 1 year after CA was evaluated, and changes in the cardiac function over 5 years after CA were also examined. QOL was assessed using the AF QOL questionnaire (AFQLQ) developed by the Japanese Heart Rhythm Society. In addition, cardiac function was assessed by measuring the plasma B-type natriuretic peptide (BNP) level, left ventricular ejection fraction (LVEF), left atrial diameter (LAD) with transthoracic echocardiogram, and left atrial (LA) volume with computed tomography (CT). The AFQLQ significantly improved after CA in terms of "symptom frequency" and "activity limits and mental anxiety." The plasma BNP level, LVEF, and LAD significantly improved in the first 3 months after the first CA, with no significant changes thereafter (from 149.0 pg/dL [95% confidence intervals {CI}, 114.5-183.5 pg/dL] to 49.8 pg/dL [95% CI, 26.5-70.1], Improvement in the QOL and cardiac function after CA of asymptomatic persistent AF was revealed. Asymptomatic persistent AF should be appropriately treated by CA.
Sections du résumé
BACKGROUND
BACKGROUND
Catheter ablation (CA) for atrial fibrillation (AF) is widely performed. However, the indication for CA in patients with asymptomatic persistent AF is still controversial.
METHODS
METHODS
Among 259 consecutive patients who were hospitalized for initial CA of AF, a total of 45 patients who had asymptomatic persistent AF were retrospectively analyzed. Quality of life (QOL) before and 1 year after CA was evaluated, and changes in the cardiac function over 5 years after CA were also examined. QOL was assessed using the AF QOL questionnaire (AFQLQ) developed by the Japanese Heart Rhythm Society. In addition, cardiac function was assessed by measuring the plasma B-type natriuretic peptide (BNP) level, left ventricular ejection fraction (LVEF), left atrial diameter (LAD) with transthoracic echocardiogram, and left atrial (LA) volume with computed tomography (CT).
RESULTS
RESULTS
The AFQLQ significantly improved after CA in terms of "symptom frequency" and "activity limits and mental anxiety." The plasma BNP level, LVEF, and LAD significantly improved in the first 3 months after the first CA, with no significant changes thereafter (from 149.0 pg/dL [95% confidence intervals {CI}, 114.5-183.5 pg/dL] to 49.8 pg/dL [95% CI, 26.5-70.1],
CONCLUSION
CONCLUSIONS
Improvement in the QOL and cardiac function after CA of asymptomatic persistent AF was revealed. Asymptomatic persistent AF should be appropriately treated by CA.
Identifiants
pubmed: 33664880
doi: 10.1002/joa3.12457
pii: JOA312457
pmc: PMC7896458
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11-19Informations de copyright
© 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.
Déclaration de conflit d'intérêts
Authors declare no conflict of interest for this article. The study protocol was approved on May 13, 2017 by a suitably constituted Ethics Committee of Tenri Hospital (no. 429), and it conforms to the provisions of the Declaration of Helsinki.
Références
J Arrhythm. 2020 Dec 11;37(1):11-19
pubmed: 33664880
Circ Arrhythm Electrophysiol. 2014 Feb;7(1):31-8
pubmed: 24382410
Cardiol Res Pract. 2020 Apr 17;2020:9583409
pubmed: 32377430
J Am Heart Assoc. 2018 Dec 4;7(23):e010256
pubmed: 30486704
Circ Arrhythm Electrophysiol. 2015 Feb;8(1):18-24
pubmed: 25528745
Am Heart J. 1998 May;135(5 Pt 1):825-32
pubmed: 9588412
J Cardiovasc Electrophysiol. 2007 Sep;18(10):1047-52
pubmed: 17655662
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
N Engl J Med. 2004 Dec 2;351(23):2373-83
pubmed: 15575053
Eur Heart J. 2010 Oct;31(19):2369-429
pubmed: 20802247
N Engl J Med. 2002 Jul 18;347(3):161-7
pubmed: 12124404
JAMA. 2001 Jun 13;285(22):2864-70
pubmed: 11401607
Heart Vessels. 2016 Jul;31(7):1140-7
pubmed: 26129869
J Thorac Dis. 2015 Dec;7(12):E575-84
pubmed: 26793367
Circ Heart Fail. 2014 Jan;7(1):154-60
pubmed: 24347664
Circ J. 2017 Mar 24;81(4):444-449
pubmed: 28123151
Circulation. 2008 Dec 9;118(24):2498-505
pubmed: 19029470
Int J Cardiol. 2015 Jan 20;179:449-54
pubmed: 25465306
JAMA. 2019 Mar 19;321(11):1059-1068
pubmed: 30874754
Circulation. 2005 Nov 8;112(19):2896-903
pubmed: 16260634
Europace. 2018 Jan 1;20(1):157-208
pubmed: 29016841
Circ J. 2003 Sep;67(9):738-41
pubmed: 12939546
Europace. 2016 Nov;18(11):1609-1678
pubmed: 27567465
Circ J. 2008 Apr;72(4):582-7
pubmed: 18362429
Europace. 2019 Mar 18;21(6):844–845
pubmed: 30882141
Behav Brain Res. 2014 Aug 15;270:112-7
pubmed: 24815213
J Am Coll Cardiol. 2009 Feb 10;53(6):483-90
pubmed: 19195605
Heart Rhythm. 2005 Jun;2(6):619-23
pubmed: 15922270
J Am Coll Cardiol. 2010 May 25;55(21):2308-16
pubmed: 20488300
Circulation. 2005 Sep 13;112(11):1580-6
pubmed: 16144994